Loading
UP
Ultragenyx Pharmaceutical Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by KAKKIS EMIL D, was filed 11 Sept 2019.
Ultragenyx Pharmaceutical Inc.: what insiders have been doing
Ultragenyx Pharmaceutical Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 44 filings came from 12 insiders.
The flow runs one way only: 22 sales worth €2.9M, from 7 insiders, and no purchase. Biggest ticket of the year: €1.1M, sold by Kakkis Emil D and made public on 3 March 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (3,171 companies, median 24 filings), a count of 44 filings is above the norm. The full history, which starts in 2016, counts 3 purchases against 270 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 673.0 m USD and net income at -575.0 m USD.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
739
Thresholds
n/a
Buy Volume
€527,336
3 ops. · all time
Sell Volume
€89M
270 ops. · all time
Who traded when
BuySaleHoward Horn12 sales
Karah Herdman Parschauer8 sales
Theodore Alan Huizenga7 sales
Emil D. Kakkis5 sales
Eric Crombez4 sales
Erik Harris2 sales
+3 other insiders
Since the insiders bought
- +65.2%Entry US$44.69 · Close at T+365 US$73.83
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ultragenyx Pharmaceutical Inc. Buy (bullish), based on 20 analysts. Average price target: US$26.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,193 of 26,248 companies
26.9
score / 100
Value7
Quality47
FCF yld-31%
Earn yld-36%
EV/EBITDA·
ROE·
Gross mgn84%
Net mgn-85%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.02
Analyst consensus
20 analystsBuy
US$16.00Target US$26.25(+64%)US$39.00
Income statement
RevenueUS$673M
Gross profitUS$564M84% margin
EBITDA-US$474M-70% margin
Net income-US$575M-81.7% margin
Valuation
PER (forward)71.0x
Beta0.35
Balance sheet & cash
Market capUS$1.6B
Total debtUS$36M
Free Cash Flow-US$487M
Profitability & ownership
ROA-24.2%
% insiders3.4%
% institutions112.7%
Last declaration on 19 October 2026
Declarations739 total
7,066 shares@ US$15.270.0075% mcap7.5% of flowCommon StockSEC:0001193125-26-425032:0
1,283 shares@ US$13.610.0012% mcap100.0% of flowCommonSEC144:0001950047-26-009497
1,283 shares@ US$13.570.0012% mcap0.8% of flowCommon StockSEC:0001193125-26-392233:0
161 shares@ US$13.990.0002% mcap0.6% of flowCommon StockSEC:0001193125-26-384878:0
1,900 shares@ US$24.920.0033% mcap2.2% of flowCommon StockSEC:0001193125-26-332547:0
4,696 shares@ US$24.920.0081% mcap8.6% of flowCommon StockSEC:0001193125-26-332536:0
4,696 shares@ US$24.920.0081% mcap42.6% of flowCommonSEC144:0001950047-26-007510
4,698 shares@ US$33.130.011% mcap11.5% of flowCommon StockSEC:0001193125-26-296128:0
4,698 shares@ US$33.130.011% mcap57.4% of flowCommonSEC144:0001950047-26-006703
3,799 shares@ US$24.350.0027% mcap100.0% of flowCommonSEC144:0001950047-26-006115
2,000 shares@ US$25.050.0015% mcap100.0% of flowCommonSEC144:0001950047-26-006073
20,241 shares0Common StockSEC:0001193125-26-177470:0
76,745 shares0Common StockSEC:0001193125-26-164308:0
34,674 shares0Common StockSEC:0001193125-26-164257:0
28,895 shares0Common StockSEC:0001193125-26-164267:0
34,674 shares0Common StockSEC:0001193125-26-164247:0
23,116 shares0Common StockSEC:0001193125-26-164297:0
28,895 shares0Common StockSEC:0001193125-26-164281:0
23,116 shares0Common StockSEC:0001193125-26-164289:0
4,683 shares@ US$20.977.2% of flowCommon StockSEC:0001193125-26-140702:0
3,508 shares@ US$22.670.6% of flowCommon StockSEC:0001193125-26-100309:1
6,018 shares@ US$21.406.0% of flowCommon StockSEC:0001193125-26-100309:0
10,029 shares@ US$22.806.1% of flowCommon StockSEC:0001193125-26-089287:1
7,029 shares@ US$22.8022.5% of flowCommon StockSEC:0001193125-26-089104:1
8,135 shares@ US$22.801.3% of flowCommon StockSEC:0001193125-26-089111:1
25 of 739 declarations
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ under the ticker RARE, with headquarters in Novato, California, United States. The company was founded to develop innovative medicines for rare and ultra-rare genetic diseases, a field defined by high unmet medical need, small patient populations, and a strong reliance on scientific differentiation. Ultragenyx describes its mission as building therapies for rare and ultra-rare diseases that have historically lacked approved treatment options, using a broad set of drug modalities to match the best therapeutic approach to each disease biology. ([ultragenyx.com](https://www.ultragenyx.com/?utm_source=openai))
From an equity analyst perspective, Ultragenyx is positioned as a specialty rare-disease platform rather than a single-asset story. Its business model combines internal discovery, clinical development, manufacturing, and commercialization, with the goal of building a diversified portfolio of marketed products and late-stage pipeline candidates. Recent company communications emphasize that Ultragenyx has multiple global products contributing to revenue growth and that management expects continued execution across upcoming commercial launches and Phase 3 programs. In its 2025 updates, the company reiterated its financial guidance and highlighted a path toward profitability over time, supported by product sales and pipeline progression. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1515673/000095017025019854/rare-ex99_1.htm?utm_source=openai))
Read moreShow less
Ultragenyx’s competitive position comes from its deep focus on rare genetic disorders, which typically require specialized clinical expertise, regulatory know-how, and long development timelines. This specialization can create meaningful barriers to entry, especially where patient identification, trial design, and global commercialization capabilities matter as much as the underlying molecule. The company’s portfolio strategy is designed to reduce dependence on any one asset by spanning approved therapies and investigational programs across multiple rare-disease indications. That diversification is particularly important in a segment where clinical readouts and regulatory decisions can materially influence valuation. ([ultragenyx.com](https://www.ultragenyx.com/?utm_source=openai))
Geographically, Ultragenyx operates beyond the United States, with activity in Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. This international footprint supports a broader commercial opportunity set and reflects the global nature of rare-disease diagnosis and treatment. Recent milestones include the company’s 2024 Impact Report, continued emphasis on rare-disease innovation, operational execution around manufacturing for gene-therapy programs, and ongoing corporate updates tied to product revenue growth and pipeline advancement. For investors in France, Belgium, and Switzerland, the key takeaway is that Ultragenyx is a specialized U.S. rare-disease company on NASDAQ, built around long-duration innovation, multi-product commercialization, and a pipeline-driven growth model. ([ir.ultragenyx.com](https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-underscores-continued-commitment-rare-disease?utm_source=openai))
